Table 1 Demographic data and patient characteristics
Patients characteristics | Groups | |||||
|---|---|---|---|---|---|---|
Cases (n = 45) | Control (n = 10) | |||||
N | % | N | % | |||
Sex | Male | 24 | 53.3 | 5 | 50.0 | |
Female | 21 | 46.7 | 5 | 50.0 | ||
Age | Range | 20.0–78.0 | 33.0–50.0 | |||
Median (IQR) | 50.0 (25) | 41.50(10.5) | ||||
Peripheral blood | TLC | Range | 1.0–236.0 | 6.0–9.0 | ||
Median (IQR) | 10.0 (38) | 7.0(2) | ||||
HB | Range | 4.0–12.0 | 10.0–14.0 | |||
Median (IQR) | 8.0 (4) | 12.0 (2.5) | ||||
PLT | Range | 4.0–345.0 | 189.0–370.0 | |||
Median (IQR) | 40.0 (61) | 230.50 (101.28) | ||||
P.B | Range | 0.0–87.0 | – | |||
Median (IQR) | 32.0 (45) | – | ||||
B.M asp | Range | 30.0–99.0 | - | |||
Median (IQR) | 70.0 (25) | - | ||||
FAB. classification | M0 | 1 | 2.2 | – | – | |
M0–M1 | 1 | 2.2 | – | – | ||
M1 | 3 | 6.7 | – | – | ||
M1–M2 | 6 | 13.3 | – | – | ||
M2 | 8 | 17.8 | – | – | ||
M3 | 3 | 6.7 | – | – | ||
M4 | 2 | 4.4 | – | – | ||
M4–M5 | 16 | 35.6 | – | – | ||
M5 | 3 | 6.7 | – | – | ||
M7 | 2 | 4.4 | – | – | ||
Risk stratification | Poor risk | 7 | 15.5 | – | – | |
Intermediate risk | 25 | 55.5 | – | – | ||
Good risk | 13 | 28.2 | – | – | ||
Remission status after induction chemotherapy | Remitted | 17 | 40.5 | – | – | |
Refractory | 8 | 17.8 | – | – | ||
Died | 20 | 44.4 | – | – | ||
DNMT3A expression before treatment | Range | 18.60–83.60 | 0.54–1.72 | |||
Median (IQR) | 46.5 (33.9) | 0.98 (0.57) | ||||
DNMT3A expression after treatment | Range | 2.96–71.20 | – | |||
Median (IQR) | 17.05 (37.4) | – | ||||
DNMT3A mutation | Mutant | 12 | 26.7 | – | – | |
Wild | 33 | 73.3 | – | – | ||
DNMT3A expression | Low expression | 22 | 48.9 | 10 | 100.0 | |
High expression | 23 | 51.1 | 0 | 0.0 | ||
NO level pre-treatment | Range | 0.53–60.90 | 0.0–22.11 | |||
Median (IQR) | 12.0 (16.78) | 5.80(9.65) | ||||
NO level post-treatment | Range | 0.0–27.50 | – | |||
Median (IQR) | 6.20(8.8) | – | ||||